These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 38061213)

  • 21. Rectal cancer patients after neoadjuvant radiotherapy (30Gy/10f) with negative lymph node may not benefit from postoperative adjuvant chemotherapy: a retrospective study.
    Chen P; Yao Y; Gu J
    Int J Colorectal Dis; 2015 Dec; 30(12):1695-704. PubMed ID: 26278877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monthly tegafur-uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study.
    Kuo YH; Lai CH; Huang CY; Chen CJ; Huang YC; Huang WS; Chin CC
    BMC Cancer; 2019 Aug; 19(1):815. PubMed ID: 31419963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Value of Lymph Node Ratio in Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy Followed by Total Mesorectal Excision.
    Zuo ZG; Zhang XF; Wang H; Liu QZ; Ye XZ; Xu C; Wu XB; Cai JH; Zhou ZH; Li JL; Song HY; Luo ZQ; Li P; Ni SC; Jiang L
    Medicine (Baltimore); 2016 Mar; 95(9):e2988. PubMed ID: 26945418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection.
    Dossa F; Acuna SA; Rickles AS; Berho M; Wexner SD; Quereshy FA; Baxter NN; Chadi SA
    JAMA Oncol; 2018 Jul; 4(7):930-937. PubMed ID: 29710274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
    Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
    Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 27. Neoadjuvant-intensified treatment for rectal cancer: time to change?
    Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
    World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Who Should Get Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiation?
    Malakorn S; Yang Y; Bednarski BK; Kaur H; You YN; Holliday EB; Dasari A; Skibber JM; Rodriguez-Bigas MA; Chang GJ
    Dis Colon Rectum; 2019 Oct; 62(10):1158-1166. PubMed ID: 31490825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment and survival of locally recurrent rectal cancer: A cross-sectional population study 15 years after the Dutch TME trial.
    Detering R; Karthaus EG; Borstlap WAA; Marijnen CAM; van de Velde CJH; Bemelman WA; Beets GL; Tanis PJ; Aalbers AGJ;
    Eur J Surg Oncol; 2019 Nov; 45(11):2059-2069. PubMed ID: 31230980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic importance of lymph node count and ratio in rectal cancer after neoadjuvant chemoradiotherapy: Results from a cross-sectional study.
    Detering R; Meyer VM; Borstlap WAA; Beets-Tan RGH; Marijnen CAM; Hompes R; Tanis PJ; van Westreenen HL;
    J Surg Oncol; 2021 Sep; 124(3):367-377. PubMed ID: 33988882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline MRI detected lateral lymph node as a prognostic factor: a cohort study in pN0 low-risk rectal cancer.
    Sun RJ; Wang L; Li XT; Lu QY; Zhang XY; Guan Z; Sun YS
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):739-748. PubMed ID: 31832762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MRI-based guidelines for selective neoadjuvant treatment in rectal cancer: Does MRI adequately predict the indication for radiotherapy in daily practice in a large teaching hospital.
    Tersteeg JJC; Crolla RMPH; Gobardhan PD; Kint PAM; Niers-Stobbe I; Boonman-de Winter L; Arnold DE; Rozema T; Schreinemakers JMJ
    Eur J Cancer Care (Engl); 2020 Mar; 29(2):e13190. PubMed ID: 31863608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonmetastatic ypt0 rectal cancer after neoadjuvant treatment and total mesorectal excision: Lessons from a retrospective multicentric cohort of 383 patients.
    Collard MK; Rullier E; Panis Y; Manceau G; Benoist S; Tuech JJ; Alves A; Laforest A; Mege D; Cazelles A; Beyer-Berjot L; Christou N; Cotte E; Lakkis Z; O'Connell L; Parc Y; Piessen G; Lefevre JH;
    Surgery; 2022 May; 171(5):1193-1199. PubMed ID: 35078629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy.
    Abdel-Misih SR; Wei L; Benson AB; Cohen S; Lai L; Skibber J; Wilkinson N; Weiser M; Schrag D; Bekaii-Saab T
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1528-1534. PubMed ID: 27956537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymph node ratio is an independent prognostic factor in node positive rectal cancer patients treated with preoperative chemoradiotherapy followed by curative resection.
    Zeng WG; Zhou ZX; Wang Z; Liang JW; Hou HR; Zhou HT; Zhang XM; Hu JJ
    Asian Pac J Cancer Prev; 2014; 15(13):5365-9. PubMed ID: 25041003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determining the survival benefit of postoperative radiotherapy in patients with pT1-3N1M0 rectal cancer undergoing total mesorectal excision: a retrospective analysis.
    Chen JH; Ye Q; Huang F
    BMC Gastroenterol; 2023 Mar; 23(1):83. PubMed ID: 36959560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
    Seddik Y; Brahmi SA; Afqir S
    Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of adjuvant chemotherapy on recurrence-free survival varies by neo-adjuvant treatment in patients with stage III rectal cancer.
    van Erning FN; Rutten HJ; van den Berg HA; Lemmens VE; van Halteren HK
    Eur J Surg Oncol; 2015 Dec; 41(12):1630-5. PubMed ID: 26437853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.